Surrozen

Surrozen company information, Employees & Contact Information

Explore related pages

Related company profiles:

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development. The company is backed by The Column Group, a leading biotechnology venture capital firm. We are currently seeking highly creative scientists to join our team, and invite you to explore career opportunities on our website.

Company Details

Employees
72
Address
171 Oyster Point Blvd, South San Francisco,california 94080,united States
Email
ca****@****zen.com
Industry
Biotechnology
HQ
South San Francisco, California
Looking for a particular Surrozen employee's phone or email?

Surrozen Questions

News

Wnt Pathway Therapeutics Pioneer Surrozen to Showcase Pipeline at Major Healthcare Conference Sept 10 - Stock Titan

Wnt Pathway Therapeutics Pioneer Surrozen to Showcase Pipeline at Major Healthcare Conference Sept 10 Stock Titan

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development - Nasdaq

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development Nasdaq

Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company - Yahoo Finance

Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company Yahoo Finance

Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease - Fierce Biotech

Surrozen drops sole clinical-stage drug over weak hepatitis data, pivots to eye disease Fierce Biotech

Surrozen drops hepatitis drug after Phase I flop - Clinical Trials Arena

Surrozen drops hepatitis drug after Phase I flop Clinical Trials Arena

Surrozen secures patent for tissue repair technology - Investing.com

Surrozen secures patent for tissue repair technology Investing.com

45,710 Shares at $12.32: Surrozen's Latest Stock Option Grants for New Biotech Talent Expansion - Stock Titan

45,710 Shares at $12.32: Surrozen's Latest Stock Option Grants for New Biotech Talent Expansion Stock Titan

Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline - Nasdaq

Surrozen Secures $175Mln In Oversubscribed Private Placement To Advance Ophthalmology Pipeline Nasdaq

Combining price and volume data for Surrozen Inc. - CEO Change & Accurate Intraday Trade Tips - newser.com

Combining price and volume data for Surrozen Inc. - CEO Change & Accurate Intraday Trade Tips newser.com

Novel Frizzled-specific antibody-based Wnt mimetics and Wnt superagonists selectively activate WNT/β-catenin signaling in target tissues - ScienceDirect.com

Novel Frizzled-specific antibody-based Wnt mimetics and Wnt superagonists selectively activate WNT/β-catenin signaling in target tissues ScienceDirect.com

Companies Like Surrozen (NASDAQ:SRZN) Are In A Position To Invest In Growth - Sahm

Companies Like Surrozen (NASDAQ:SRZN) Are In A Position To Invest In Growth Sahm

StemPoint Capital LP Increases Stake in Surrozen Inc - GuruFocus

StemPoint Capital LP Increases Stake in Surrozen Inc GuruFocus

How Surrozen Inc. stock responds to policy changes - July 2025 Summary & Consistent Return Strategy Ideas - Trung tâm Dự báo KTTV quốc gia

How Surrozen Inc. stock responds to policy changes - July 2025 Summary & Consistent Return Strategy Ideas Trung tâm Dự báo KTTV quốc gia

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules Yahoo Finance

Real time alert setup for Surrozen Inc. performance - July 2025 News Drivers & High Accuracy Investment Signals - newser.com

Real time alert setup for Surrozen Inc. performance - July 2025 News Drivers & High Accuracy Investment Signals newser.com

How Surrozen Inc. Equity Warrant stock performs in rate cut cycles - Buy Signal & Comprehensive Market Scan Reports - Trung tâm Dự báo KTTV quốc gia

How Surrozen Inc. Equity Warrant stock performs in rate cut cycles - Buy Signal & Comprehensive Market Scan Reports Trung tâm Dự báo KTTV quốc gia

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - Stock Titan

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration Stock Titan

Predicting Surrozen Inc. Equity Warrant trend using moving averages - IPO Watch & Free Technical Pattern Based Buy Signals - newser.com

Predicting Surrozen Inc. Equity Warrant trend using moving averages - IPO Watch & Free Technical Pattern Based Buy Signals newser.com

Can Surrozen Inc. stock sustain institutional interest - 2025 EndofYear Setup & Precise Buy Zone Identification - Trung tâm Dự báo KTTV quốc gia

Can Surrozen Inc. stock sustain institutional interest - 2025 EndofYear Setup & Precise Buy Zone Identification Trung tâm Dự báo KTTV quốc gia

Momentum divergence signals in Surrozen Inc. Equity Warrant chart - Trade Volume Report & Low Risk Profit Maximizing Plans - newser.com

Momentum divergence signals in Surrozen Inc. Equity Warrant chart - Trade Volume Report & Low Risk Profit Maximizing Plans newser.com

Surrozen announces partnership with Boehringer Ingelheim to develop Wnt agonist SZN-413 for people diagnosed with retinal diseases - Ophthalmology Times

Surrozen announces partnership with Boehringer Ingelheim to develop Wnt agonist SZN-413 for people diagnosed with retinal diseases Ophthalmology Times

Surrozen stops IBD program due to dose concerns and competition - Fierce Biotech

Surrozen stops IBD program due to dose concerns and competition Fierce Biotech

Surrozen’s Collaboration Agreement with TCGFB Terminated - TipRanks

Surrozen’s Collaboration Agreement with TCGFB Terminated TipRanks

Design principles and therapeutic applications of novel synthetic WNT signaling agonists - ScienceDirect.com

Design principles and therapeutic applications of novel synthetic WNT signaling agonists ScienceDirect.com

Liver enzyme elevations in healthy volunteers prompts soul searching at Surrozen - Fierce Biotech

Liver enzyme elevations in healthy volunteers prompts soul searching at Surrozen Fierce Biotech

How Surrozen Inc. Equity Warrant stock performs in rate cut cycles - New Guidance & Low Risk Entry Point Guides - Fundação Cultural do Pará

How Surrozen Inc. Equity Warrant stock performs in rate cut cycles - New Guidance & Low Risk Entry Point Guides Fundação Cultural do Pará

Is Surrozen Inc. stock a dividend growth opportunity - Stock Surge & Weekly Return Optimization Plans - Fundação Cultural do Pará

Is Surrozen Inc. stock a dividend growth opportunity - Stock Surge & Weekly Return Optimization Plans Fundação Cultural do Pará

Surrozen culls at least 2 research programs to funnel more money toward clinical work - Fierce Biotech

Surrozen culls at least 2 research programs to funnel more money toward clinical work Fierce Biotech

Is Surrozen Inc. stock affected by interest rate hikes - Market Rally & Accurate Entry/Exit Alerts - Trung tâm Dự báo KTTV quốc gia

Is Surrozen Inc. stock affected by interest rate hikes - Market Rally & Accurate Entry/Exit Alerts Trung tâm Dự báo KTTV quốc gia

Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway - BioSpace

Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway BioSpace

Boehringer sets sights on Surrozen's preclinical retinal disease asset in $600M deal - Fierce Biotech

Boehringer sets sights on Surrozen's preclinical retinal disease asset in $600M deal Fierce Biotech

Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld MedTech

Boehringer Ingelheim to advance SZN-413 for retinal diseases BioWorld MedTech

Surrozen cuts inflammatory bowel disease drug as cash, stock drop - The Business Journals

Surrozen cuts inflammatory bowel disease drug as cash, stock drop The Business Journals

Alyeska Investment Group L.P. Expands Portfolio with Surrozen In - GuruFocus

Alyeska Investment Group L.P. Expands Portfolio with Surrozen In GuruFocus

H.C. Wainwright Maintains Surrozen(SRZN.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛

H.C. Wainwright Maintains Surrozen(SRZN.US) With Buy Rating, Maintains Target Price $32 富途牛牛

Surrozen, Inc. Receives Notice from TCGFB, Inc. to Terminate the Collaboration Agreement - MarketScreener

Surrozen, Inc. Receives Notice from TCGFB, Inc. to Terminate the Collaboration Agreement MarketScreener

Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal - Fierce Biotech

Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal Fierce Biotech

What are the technical indicators suggesting about Surrozen Inc. - Capitalize on market trends with confidence - Jammu Links News

What are the technical indicators suggesting about Surrozen Inc. - Capitalize on market trends with confidence Jammu Links News

Smart Money: Is Surrozen Inc. stock affected by interest rate hikes - Weekly Stock Analysis & Real-Time Volume Trigger Notifications - Fundação Cultural do Pará

Smart Money: Is Surrozen Inc. stock affected by interest rate hikes - Weekly Stock Analysis & Real-Time Volume Trigger Notifications Fundação Cultural do Pará

Surrozen Chooses TransPerfect’s Trial Interactive eClinical Platform for Comprehensive TMF Management - Business Wire

Surrozen Chooses TransPerfect’s Trial Interactive eClinical Platform for Comprehensive TMF Management Business Wire

Wnt-focused Surrozen bags $50M to push regenerative medicine for liver disease - Fierce Biotech

Wnt-focused Surrozen bags $50M to push regenerative medicine for liver disease Fierce Biotech

Surrozen (SRZN) Stock Price, News & Analysis - MarketBeat

Surrozen (SRZN) Stock Price, News & Analysis MarketBeat

Critical Contrast: Surrozen (NASDAQ:SRZN) and Scienture (NASDAQ:SCNX) - Defense World

Critical Contrast: Surrozen (NASDAQ:SRZN) and Scienture (NASDAQ:SCNX) Defense World

Top Surrozen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant